[8-K] Atara Biotherapeutics, Inc Reports Material Event
Atara Biotherapeutics reported that it announced financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1 to its Form 8-K. The filing specifies the press release is being furnished (not "filed") and therefore is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act or deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference into other SEC filings unless expressly referenced. The Form lists the company ticker as ATRA and is signed by the Chief Accounting Officer.
Atara Biotherapeutics ha annunciato i risultati finanziari per il secondo trimestre chiuso al 30 giugno 2025 e ha fornito un comunicato stampa come Exhibit 99.1 al proprio Modulo 8-K. Il deposito indica che il comunicato 猫 stato fornito (non 'presentato') e pertanto non 猫 soggetto alle responsabilit脿 previste dalle Sezioni 11 e 12(a)(2) del Securities Act n茅 猫 considerato 'presentato' ai sensi della Sezione 18 dell'Exchange Act, e non sar脿 incorporato per riferimento in altri documenti trasmessi alla SEC salvo espressa indicazione. Il modulo riporta il ticker aziendale ATRA ed 猫 firmato dal Chief Accounting Officer.
Atara Biotherapeutics inform贸 que anunci贸 los resultados financieros del segundo trimestre cerrado el 30 de junio de 2025 y adjunt贸 un comunicado de prensa como Exhibit 99.1 a su Formulario 8-K. La presentaci贸n especifica que el comunicado ha sido proporcionado (no 'presentado') y, por tanto, no est谩 sujeto a las responsabilidades de las Secciones 11 y 12(a)(2) del Securities Act ni se considera 'presentado' en virtud de la Secci贸n 18 del Exchange Act, y no se incorporar谩 por referencia en otros documentos presentados ante la SEC salvo que se haga referencia expresa. El Formulario indica el ticker de la compa帽铆a ATRA y est谩 firmado por el director de contabilidad.
Atara Biotherapeutics電� 2025雲� 6鞗� 30鞚检瀽搿� 膦呺霅� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頄堨溂氅�, 氤措弰鞛愲毳� Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖(鞝滉车)頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滊姅 氤措弰鞛愲臧� 鞝滉车霅� 瓴�('鞝滌稖霅�' 鞎勲嫎)鞙茧 氇呾嫓頃橁碃 鞛堨柎, 鞚措姅 Securities Act鞚� 靹轨厴 11 氚� 12(a)(2)鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅� Exchange Act鞚� 靹轨厴 18鞐� 霐半澕 '鞝滌稖霅�' 瓴冹溂搿� 臧勳＜霅橃 鞎婈碃, 氇呾嫓鞝侅溂搿� 彀胳“霅橃 鞎婋姅 頃� 雼るジ SEC 鞝滌稖靹滊鞐� 鞚橅晿鞐� 彀胳“搿� 韱淀暕霅橃 鞎婌姷雼堧嫟. 頃措嫻 Form鞐愲姅 須岇偓鞚� 韹办护臧� ATRA搿� 旮办灛霅橃柎 鞛堨溂氅� 斓滉碃須岅硠毂呾瀯鞛�(Chief Accounting Officer)臧� 靹滊獏頄堨姷雼堧嫟.
Atara Biotherapeutics a annonc茅 les r茅sultats financiers du deuxi猫me trimestre clos le 30 juin 2025 et a fourni un communiqu茅 de presse en tant que Exhibit 99.1 脿 son formulaire 8-K. Le d茅p么t pr茅cise que le communiqu茅 a 茅t茅 fourni (et non 'd茅pos茅') et n'est donc pas soumis aux responsabilit茅s des Sections 11 et 12(a)(2) du Securities Act, ni consid茅r茅 comme 'd茅pos茅' au titre de la Section 18 de l'Exchange Act ; il ne sera pas incorpor茅 par renvoi dans d'autres d茅p么ts aupr猫s de la SEC sauf mention expresse. Le formulaire indique le ticker de la soci茅t茅 ATRA et est sign茅 par le Chief Accounting Officer.
Atara Biotherapeutics teilte mit, dass es die Finanzergebnisse f眉r das zum 30. Juni 2025 beendete zweite Quartal bekannt gegeben und eine Pressemitteilung als Exhibit 99.1 zu seiner Form 8-K bereitgestellt hat. Die Einreichung weist darauf hin, dass die Pressemitteilung bereitgestellt wurde (nicht 'eingereicht') und daher nicht den Haftungsregelungen der Sections 11 und 12(a)(2) des Securities Act unterliegt und gem盲脽 Section 18 des Exchange Act nicht als 'eingereicht' gilt; sie wird nicht per Verweis in andere SEC-Einreichungen aufgenommen, es sei denn, dies wird ausdr眉cklich angegeben. Das Formular nennt das Unternehmens-Ticker ATRA und ist vom Chief Accounting Officer unterzeichnet.
- None.
- None.
Insights
TL;DR: The 8-K furnishes a Q2 results press release but contains no financial figures in the filing itself.
The filing confirms Atara has publicly announced second-quarter 2025 results via a press release attached as Exhibit 99.1. The Form explicitly treats the release as "furnished," which limits certain statutory liabilities. Because the 8-K text provided here does not include the underlying financial metrics or operational detail, this specific filing is informational and of limited standalone materiality; material impact depends on the contents of Exhibit 99.1.
TL;DR: The Form emphasizes legal treatment of the press release (furnished, not filed), which is standard disclosure practice.
The company follows common practice by furnishing its earnings release and stating it is not "filed" for purposes of certain Exchange Act and Securities Act liabilities. The filing includes an authorized signature from the Chief Accounting Officer, indicating appropriate officer-level attestation for the disclosure. There are no governance changes or additional corporate actions disclosed in this 8-K.
Atara Biotherapeutics ha annunciato i risultati finanziari per il secondo trimestre chiuso al 30 giugno 2025 e ha fornito un comunicato stampa come Exhibit 99.1 al proprio Modulo 8-K. Il deposito indica che il comunicato 猫 stato fornito (non 'presentato') e pertanto non 猫 soggetto alle responsabilit脿 previste dalle Sezioni 11 e 12(a)(2) del Securities Act n茅 猫 considerato 'presentato' ai sensi della Sezione 18 dell'Exchange Act, e non sar脿 incorporato per riferimento in altri documenti trasmessi alla SEC salvo espressa indicazione. Il modulo riporta il ticker aziendale ATRA ed 猫 firmato dal Chief Accounting Officer.
Atara Biotherapeutics inform贸 que anunci贸 los resultados financieros del segundo trimestre cerrado el 30 de junio de 2025 y adjunt贸 un comunicado de prensa como Exhibit 99.1 a su Formulario 8-K. La presentaci贸n especifica que el comunicado ha sido proporcionado (no 'presentado') y, por tanto, no est谩 sujeto a las responsabilidades de las Secciones 11 y 12(a)(2) del Securities Act ni se considera 'presentado' en virtud de la Secci贸n 18 del Exchange Act, y no se incorporar谩 por referencia en otros documentos presentados ante la SEC salvo que se haga referencia expresa. El Formulario indica el ticker de la compa帽铆a ATRA y est谩 firmado por el director de contabilidad.
Atara Biotherapeutics電� 2025雲� 6鞗� 30鞚检瀽搿� 膦呺霅� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頄堨溂氅�, 氤措弰鞛愲毳� Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖(鞝滉车)頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滊姅 氤措弰鞛愲臧� 鞝滉车霅� 瓴�('鞝滌稖霅�' 鞎勲嫎)鞙茧 氇呾嫓頃橁碃 鞛堨柎, 鞚措姅 Securities Act鞚� 靹轨厴 11 氚� 12(a)(2)鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅� Exchange Act鞚� 靹轨厴 18鞐� 霐半澕 '鞝滌稖霅�' 瓴冹溂搿� 臧勳＜霅橃 鞎婈碃, 氇呾嫓鞝侅溂搿� 彀胳“霅橃 鞎婋姅 頃� 雼るジ SEC 鞝滌稖靹滊鞐� 鞚橅晿鞐� 彀胳“搿� 韱淀暕霅橃 鞎婌姷雼堧嫟. 頃措嫻 Form鞐愲姅 須岇偓鞚� 韹办护臧� ATRA搿� 旮办灛霅橃柎 鞛堨溂氅� 斓滉碃須岅硠毂呾瀯鞛�(Chief Accounting Officer)臧� 靹滊獏頄堨姷雼堧嫟.
Atara Biotherapeutics a annonc茅 les r茅sultats financiers du deuxi猫me trimestre clos le 30 juin 2025 et a fourni un communiqu茅 de presse en tant que Exhibit 99.1 脿 son formulaire 8-K. Le d茅p么t pr茅cise que le communiqu茅 a 茅t茅 fourni (et non 'd茅pos茅') et n'est donc pas soumis aux responsabilit茅s des Sections 11 et 12(a)(2) du Securities Act, ni consid茅r茅 comme 'd茅pos茅' au titre de la Section 18 de l'Exchange Act ; il ne sera pas incorpor茅 par renvoi dans d'autres d茅p么ts aupr猫s de la SEC sauf mention expresse. Le formulaire indique le ticker de la soci茅t茅 ATRA et est sign茅 par le Chief Accounting Officer.
Atara Biotherapeutics teilte mit, dass es die Finanzergebnisse f眉r das zum 30. Juni 2025 beendete zweite Quartal bekannt gegeben und eine Pressemitteilung als Exhibit 99.1 zu seiner Form 8-K bereitgestellt hat. Die Einreichung weist darauf hin, dass die Pressemitteilung bereitgestellt wurde (nicht 'eingereicht') und daher nicht den Haftungsregelungen der Sections 11 und 12(a)(2) des Securities Act unterliegt und gem盲脽 Section 18 des Exchange Act nicht als 'eingereicht' gilt; sie wird nicht per Verweis in andere SEC-Einreichungen aufgenommen, es sei denn, dies wird ausdr眉cklich angegeben. Das Formular nennt das Unternehmens-Ticker ATRA und ist vom Chief Accounting Officer unterzeichnet.
FAQ
What did Atara Biotherapeutics (ATRA) disclose in this Form 8-K?
Does the 8-K include the actual financial figures for Q2 2025?
Is the press release considered "filed" with the SEC?
Where is the press release referenced in the 8-K?
Who signed the Form 8-K for Atara Biotherapeutics?
